A Randomized Feasibility Study Evaluating Temozolomide Chronotherapy for High Grade Glioma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 30 Apr 2018
At a glance
- Drugs Temozolomide (Primary)
- Indications Glioblastoma; Glioma
- Focus Therapeutic Use
- 24 Apr 2018 Planned End Date changed from 30 Nov 2019 to 30 Jan 2020.
- 24 Apr 2018 Planned primary completion date changed from 31 Dec 2018 to 20 Oct 2018.
- 24 Apr 2018 Status changed from recruiting to active, no longer recruiting.